Share Name Share Symbol Market Type Share ISIN Share Description
Immunodiagnostic Systems Holdings Plc LSE:IDH London Ordinary Share GB00B01YZ052 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 270.00p 260.00p 280.00p 270.00p 270.00p 270.00p 0 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 38.5 0.8 2.7 100.0 78

Immunodiagnostic Systems Share Discussion Threads

Showing 676 to 699 of 900 messages
Chat Pages: 36  35  34  33  32  31  30  29  28  27  26  25  Older
DateSubjectAuthorDiscuss
28/11/2011
07:54
Three days ago... LONDON (Dow Jones)--U.K. diagnostics firm Omega Diagnostics Group PLC (ODX.LN) is planning to establish a direct sales presence in the U.S. market to capitalize on the launch next year of a range of automated diagnostic tests, the company's sales director said Friday. Omega currently has its own sales forces in the U.K., Germany, and India, and sells through distributors to all major markets around the world. The establishment of a direct U.S. presence "features in [the company's] plans" over the next year, Sales Director Jag Grewal told Dow Jones Newswires. In March the company signed an exclusive worldwide deal to develop allergy tests for Immunodiagnostic Systems Holdings PLC's (IDH.LN) flagship IDS-iSYS analyzer instrument. Omega plans to launch tests for between 50 and 100 common allergies during 2012, Chief Executive Andrew Shepherd told Dow Jones Newswires. The iSYS machine can process 250 tests a day, compared with around 20 or 30 in a week for Omega's existing manual tests, so will open up a new market of larger clinical laboratories to the company, according to Shepherd. The company has previously said the launch of iSYS tests will help it accelerate revenue growth. Comparable revenue was up 6.5% in the six months ended Sept. 30. -------------------------------------------------------------------------------------------------------------------------------------- Today, not much of a profit warning due to the increase in competition..... Outlook As we announced at the time of our full year results in June, we expect the demand for vitamin D testing will continue to grow, albeit at lower rates than experienced in recent years. This appears to be the case with growth continuing in both manual and automated testing. The impending introduction of competing automated products from some major manufacturers has coincided with efforts to contain health budgets, particularly in the USA. As a result we are beginning to see increasing price pressure, particularly on our larger accounts, and some disruption to equipment ordering patterns which we believe will persist in the short term and it is likely that this will impact negatively on our placement rate for the current period. As we noted earlier there are a number of global account discussions that are underway although the likely outcome and duration of these discussions remains uncertain.
spacecake
28/11/2011
07:26
Gone ex growth, costs out of control. Revenue up nearly 5m only 10% of which fell to bottom line.
philo124
24/11/2011
10:10
Not currently a holder, but I would not necessarily say that a warning is coming. IDH share price action mirrors many other small caps currently, where bad news has neither appeared nor seems imminent. May well be market led not IDH led.
pentangle
23/11/2011
15:50
The rapid descent in the share price is indicative of a forthcoming warning - things do not happen like this for no reason.
alftupper
21/10/2011
13:38
I think it's more because one of their competitors said the Vitamin D testing market was reaching saturation.
wjccghcc
21/10/2011
08:17
Spot on pentangle, i did the same fwiw, but would buy in again on a very bad day if it arises.
philo124
20/10/2011
10:59
I think it is indicative of the state of the stock market at present rather than anything sinister happening to the company AFAIK. People have made a lot of money on IDH and are tending to grab profits whilst they are still there. I had a lot of these, but sold out north of £11 (should have hung on for nearly a pound more), not because I had lost faith in the company, but because at a prospective PER of nearly 20 they did not look very cheap to me. May be tempted to buy back in if they go much lower!! At a prospective PER of under 15 they are not bad value.
pentangle
20/10/2011
10:38
something has gone wrong here - it has lost 25% plus of its value in just over a month
alftupper
14/10/2011
11:23
Gapped down today, strange after the good trading update. Is the high PE ratio holding this back ?, might we see 850p again?
spacecake
07/10/2011
13:03
Hate the rental model but you can't knock the numbers - new comment in Small Cap Review www.investorschampion.com
energeticbacker
06/10/2011
12:13
Yes, but much better than a poor update which would see the stock trashed.
alter ego
06/10/2011
11:49
Yes.In this market price imo is up with events, which i know is a bit harsh.
philo124
06/10/2011
10:55
good trading update
alter ego
15/8/2011
19:23
what a buying opportunity, so I bought
silverfern
04/8/2011
14:17
Wow, down about 20% in a few days !
spacecake
28/7/2011
07:38
So it did get to £12. I sold.
philo124
01/7/2011
18:22
Or Not. V Good close.
philo124
01/7/2011
14:32
Allergies might be a good idea.
philo124
01/7/2011
14:13
MEDICAL test firm Immunodiagnostic Systems Holdings is on the look-out for suitable acquisitions as it bids to boost the number of tests available on its inautomated system. IDS launched the IDS-iSYS machine to offer effective and speedy testing for clinical and research customers, and has expanded its range of tests from one to nine. However, the Boldon-based firm aims to boost the number of assays it can provide in the next few years, and is interested in making company acquisitions to expand its portfolio of tests. The company hopes to add another 12 assays in the next two years. CEO Ian Cookson said: "I can't say where they will be, but that's our strategy going forward." IDS currently provides testing kits for hypertension, bone testing and growth disorders, and is one of the major testers for Vitamin D in the world. It also has tests for diabetes on the horizon, but these will not emerge for several years. It expects sales of £58.6m in 2012, increasing to £68.3m in 2013 and £75.8m in 2014, and plans to increase its North East workforce by around 50 in this time. http://www.nebusiness.co.uk/business-news/latest-business-news/2011/06/28/medical-test-firm-ids-is-looking-to-expand-51140-28951569/
spacecake
30/6/2011
11:39
Breaking free at last. This completes a rather neat inverse head and shoulders continuation pattern below £10 going back to October. Upward trend renewed and at least £2 in the current move if the tealeaves mean anything.
jon l
29/6/2011
00:07
56.6p, 2012. in fairness they see eps growth slowing in 2013/2014; 67p and 75p respectively.
philo124
28/6/2011
20:47
What are the Brewin eps forecasts for this year?
valustar1
28/6/2011
20:43
Phil - can you paste the note here if poss? Glad I bought back in after Japan.
dasv
28/6/2011
18:23
Pretty High volume today.
philo124
Chat Pages: 36  35  34  33  32  31  30  29  28  27  26  25  Older
Your Recent History
LSE
IDH
Immunodiag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191016 03:03:58